Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HPB-001
- Development stage
- Preclinical
- Lead developer
- Hangzhou Polymed Biopharmaceuticals
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
01
Overview
HPB-001 is an AI-designed, small-molecule proteolysis-targeting chimera (PROTAC) being developed by Hangzhou Polymed Biopharmaceuticals (also known as Hangzhou Multi-Domain Biotechnology) for the treatment of cancer, specifically non-small cell lung cancer (NSCLC). It is designed to target and degrade the epidermal growth factor receptor (EGFR), with a particular focus on oncogenic driver mutations such as EGFR exon 20 insertion mutations. Due to the unique allosteric structure of these targets, they are often resistant or poorly responsive to conventional small-molecule kinase inhibitors. By utilizing targeted protein degradation (TPD) via the ubiquitin-proteasome system, HPB-001 aims to overcome these resistance mechanisms and completely shut down downstream oncogenic signaling. The drug is currently in preclinical development.
02
Targets
Beyond the preview
Go deeper on HPB-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HPB-001.